PURE Bioscience Engages Liolios Group to Lead New Investor Relations Program

PURE Bioscience Engages Liolios Group to Lead New Investor Relations Program 
SAN DIEGO, CA -- (Marketwire) -- 03/11/13 --  PURE Bioscience
(NASDAQ: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, has engaged Liolios Group to lead a new investor
relations and financial communications campaign. 
"Our SDC molecule quickly and completely eliminates the triple threat
of viruses, bacteria and fungus, yet is 'generally recognized as
safe' as a contact biocide," said Michael L. Krall, president and CEO
of PURE Bioscience. "Our focused technical sales strategy is creating
increasing market recognition and acceptance of our patented PURE(TM)
products across a broad range of industries and applications." 
"Given this growing momentum, we believe it's an ideal time to engage
the Liolios Group team of experienced investor relations
professionals to communicate our developing story to the investment
community and help navigate the capital markets," continued Krall.
"Liolios Group brings a proven track record of helping companies like
PURE to deliver the right message to the right audience, and we
intend to leverage its capabilities to build new, high-quality,
long-term relationships in the financial community." 
Liolios Group will collaborate with PURE Bioscience management to
strengthen the company's investor communications activity and expand
its interaction with the investment community. 
One of the many products based upon the company's SDC technology
platform includes the EPA-registered PURE(TM) Hard Surface
disinfectant and food contact surface sanitizer. PURE Hard Surface
provides an unparalleled combination of high efficacy and low
toxicity with 30-second bacterial kill times and 24-hour residual
protection. It completely kills resistant pathogens like CRE and
MRSA, while also effectively eliminating dangerous fungi and viruses,
including HIV, Norovirus, Influenza A, Avian Influenza and H1N1. PURE
Hard Surface is registered for use on food contact surfaces and is
gentle enough to be used near children. 
For more information about PURE Bioscience, contact Liolios Group at
949-574-3860 or email PURE@liolios.com. 
About Liolios Group, Inc.
 Liolios Group is a highly selective and
comprehensive investor relations firm specializing in smal
l and
micro-cap companies. The firm aims to deliver superior performance in
corporate messaging and positioning, investor awareness, analyst and
financial press coverage, and capital attraction. Founded in 1999,
Liolios Group executives have extensive experience in finance and
investments, and represent clients in a wide range of industries,
including life sciences/healthcare, consumer/Internet retail,
business services, digital media/software, clean technology,
technology and natural resources/special situations. For more
information about Liolios Group, visit www.liolios.com. 
About PURE Bioscience, Inc.
 PURE Bioscience, Inc. develops and
markets technology-based bioscience products that provide solutions
to numerous global health challenges, including Staph (MRSA) and
Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. PURE's
proprietary high efficacy/low toxicity bioscience technologies,
including its silver dihydrogen citrate-based antimicrobials,
represent innovative advances in diverse markets and lead today's
global trend toward industry and consumer use of "green" products
while providing competitive advantages in efficacy and safety.
Patented SDC is an electrolytically generated source of stabilized
ionic silver, which formulates well with other compounds. As a
platform technology, SDC is distinguished from competitors in the
marketplace because of its superior efficacy, reduced toxicity and
the inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com. 
Forward-looking Statements
 This press release includes statements
that may constitute "forward-looking" statements, usually containing
the words "believe," "estimate," "expect," "intend," "project" or
similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed initiatives and business plans, acceptance of the Company's
current and future products and services in the marketplace, the
ability of the Company to develop effective new products and receive
regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release. 
Investor Relations Contact:
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
PURE@liolios.com 
 
 
Press spacebar to pause and continue. Press esc to stop.